FDA's Priorities for Priority Review Vouchers
This article was originally published in RPM Report
Executive Summary
The evolution of the tropical disease voucher program into a full-fledged market depends heavily on how FDA implements the program. It's not just that the agency has to show that the vouchers will actually buy something of value: the agency also has to allow them to behave like a security.
You may also be interested in...
Novartis Coartem NDA May Lead to First Priority Review Voucher
Malaria drug receives "priority" status from FDA, which should mean Novartis receives a voucher for priority designation on another product under new incentive program for tropical disease research. December application deadline also sets a deadline for FDA to defi ne key elements of how PRVs will work.
Treat and Trade: The New Priority Review Voucher Market
Starting in September, pharmaceutical companies will have the opportunity to buy the right to a faster FDA review on the open market. If it works, the priority review voucher program could revolutionize development of drugs for neglected diseases, while increasing the value of more traditional commercial products in the US.
Treat and Trade: The New Priority Review Voucher Market
Starting in September, pharmaceutical companies will have the opportunity to buy the right to a faster FDA review on the open market. If it works, the priority review voucher program could revolutionize development of drugs for neglected diseases, while increasing the value of more traditional commercial products in the US.